RBS-001 vs Eylea for Age-Related Macular Degeneration
What You Need to Know Before You Apply
What is the purpose of this trial?
This clinical study is designed to demonstrate the equivalence of the two Investigational Products by comparing the efficacy, safety, tolerability and immunogenicity of RBS-001 and Eylea® in subjects with Neovascular age-related macular degeneration.
Will I have to stop taking my current medications?
The trial does not specify if you must stop taking your current medications. However, you cannot participate if you are using medications known to be toxic to the eye or if you have used certain treatments like systemic anti-VEGF therapy or systemic corticosteroids recently. It's best to discuss your specific medications with the trial team.
Is RBS-001 (Eylea) safe for humans?
How is the treatment RBS-001 different from other treatments for age-related macular degeneration?
RBS-001 is unique because it is being compared to Eylea®, a standard treatment for age-related macular degeneration, and may involve a novel approach or component not detailed in the available research. The studies mention epimacular brachytherapy (EMB), a treatment that uses targeted radiation, which could suggest a different mechanism of action compared to traditional drug therapies.678910
What data supports the effectiveness of the drug Eylea for age-related macular degeneration?
Research shows that Eylea (aflibercept) can improve visual function and reduce central macular thickness in patients with age-related macular degeneration who did not respond to other treatments. Studies also report positive anatomical and functional outcomes in patients treated with Eylea for this condition.1112131415
Are You a Good Fit for This Trial?
This trial is for individuals with Neovascular Age-Related Macular Degeneration. Specific eligibility criteria are not provided, but typically participants must meet certain health standards and have the condition being studied.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either RBS-001 or Eylea® for 48 weeks to compare efficacy, safety, tolerability, and immunogenicity
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Eylea®
- RBS-001
Find a Clinic Near You
Who Is Running the Clinical Trial?
Rophibio, Inc.
Lead Sponsor